Ga68 Imaging. Roland HUSTINX Division of Nuclear Medicine and Oncologic Imaging Centre Hospitalier Universitaire de Liège Belgium

Similar documents
Physical Bases : Which Isotopes?

Molecular Imaging in Prostate Cancer. Carlos Artigas Nuclear Medicine Institut Jules Bordet

Nuclear Medicine in Oncology

Objective. Assessment Question. I. Theranostics II. Classic Theranostic Agent

Dr. Sandip Basu Radiation Medicine Center (BARC) Tata Memorial Centre Annexe, Parel, Mumbai

Quantitative Theranostics in Nuclear Medicine

SARCOPHAGINE CHELATORS AND COPPER ISOTOPES FOR IMAGING AND THERAPY

Theranostics in Nuclear Medicine

Preclinical imaging and therapy. Marion de Jong

Tumori Neuroendocrini - Imaging perioperatorio. Annibale Versari Medicina Nucleare, Az.Osp. S.Maria Nuova-IRCCS - Reggio Emilia

Ga 68 -HBED- PSMA. A/ProfLouise Emmett St Vincent s Hospital Sydney

στη σταδιοποίηση του καρκίνου του προστάτη Γ. Αρσος, Γ Εργ. Πυρηνικής Ιατρικής ΑΠΘ, ΓΝΘ Παπαγεωργίου

Radiopharmacy. Prof. Dr. Çetin ÖNSEL. CTF Nükleer Tıp Anabilim Dalı

F NaF PET/CT in the Evaluation of Skeletal Malignancy

INDICATIONS AND USAGE

FMU-ICRP Workshop on Radiological Protection in Medicine Current Status in Radionuclide Therapy Tuesday, October 3, 2017 Makoto Hosono, MD PhD Kindai

PSMA PET SCANNING AND THERANOSTICS IN PROSTATE CANCER KEVIN TRACEY, MD, FRCPC PRECISION DIAGNSOTIC IMAGING REGIONAL PET/CT CENTRE

New imaging techniques: let there be light. Felix M. Mottaghy Department of Nuclear Medicine University Hospital KU Leuven

Neuroendocrine Tumors Positron Emission Tomography (PET) Imaging and Peptide Receptor Radionuclide Therapy

PET-MRI in malignant bone tumours. Lars Stegger Department of Nuclear Medicine University Hospital Münster, Germany

Using PET/CT in Prostate Cancer

Molecular Imaging of Bone Metastasis Hojjat Ahmadzadehfar

Short summary of published results of PET with fluoromethylcholine (18F) in prostate cancer

F-18 and Ga-68: Potentially «Deadly Poisons» for Conventional Nuclear Medicine?

Understanding Biological Activity to Inform Drug Development

Lutetium-177 PSMA (LuPSMA) Theranostic Phase II trial: Efficacy, safety and QoL in patients

Nuclear pulmonology. Katalin Zámbó Department of Nuclear Medicine

Austin Radiological Association Ga-68 NETSPOT (Ga-68 dotatate)

Lu-DOTATATE PRRT dosimetry:

Chapter 23 Clinical Efficacy of PET/CT Using

Principles of nuclear metabolic imaging. Prof. Dr. Alex Maes AZ Groeninge Kortrijk and KULeuven Belgium

The Use of PET Scanning in Urologic Oncology

Methods of nuclear medicine

Nuclear Medicine related studies for Prostate cancer

Indications of PET/CT in oncology

Hepatic metastases of neuroendocrine tumors: treatment options and outcomes of local patients treated with radioembolization

Dosimetry and radiobiology for Peptide Receptor Radionuclide Therapy

FLUCICLOVINE: 1 ST FDA APPROVED F-18 PET IMAGING AGENT FOR RECURRENT PROSTATE CANCER

Page 1 of CONTRAINDICATIONS None (4)

Molecular Imaging of NET

J Reinfelder, M Beck, P Goebell, P Ritt, J Sanders, T Kuwert, B Wullich, D Schmidt

PET imaging of cancer metabolism is commonly performed with F18

PET/CT in oncology. Positron emission tomography

New Visions in PET: Surgical Decision Making and PET/CT

Assessment of Skeletal Metastases in Prostate Cancer: 68Ga-PSMA PET vs 99mTc-MDP WBBS - A Case Series

How to optimize diagnostic nuclear techniques?

Peptide Receptor Radionuclide Therapy using 177 Lu octreotate

The PET-NET Study 2016 CNETS Grant Award

Assessment of renal cell carcinoma by two PET tracer : dual-time-point C-11 methionine and F-18 fluorodeoxyglucose

Prostate Cancer and PSMA:

Nuclear Medicine in the Diabetic Foot

Lu 177-Dotatate (Lutathera) Therapy Information

DOTATOC PET/CT: a prospective study of 59 patients with

Radionuclide Therapy: History, Present and Future Promise. History of Radionuclide (RN) Therapy. History of RN Therapy 8/2/2017

Specialised Services Policy CP66: 68-gallium DOTA- peptide scanning for the Management of Neuroendocrine Tumours (NETs)

Molecular Imaging Guided Therapy: The Perfect Storm. David M Schuster, MD Emory University Department of Radiology Atlanta, GA

PET-CT for radiotherapy planning in lung cancer: current recommendations and future directions

Positron Emission Tomography in Lung Cancer

Hybrid Imaging SPECT/CT PET/CT PET/MRI. SNMMI Southwest Chapter Aaron C. Jessop, MD

Department of Nuclear Medicine with Positron Emission Tomography

PET/CT Value: Rocky Mountain Cancer Centers

Radionuclid Therapy. dr. Erzsébet Schmidt Dept. of Nuclear Medicine University of Pécs

Case Report. Ameya D. Puranik, MD, FEBNM; Harshad R. Kulkarni, MD; Aviral Singh, MD; Richard P. Baum, MD, PhD ABSTRACT

Nuclear Medicine Head and Neck Region. Bán Zsuzsanna, MD University of Pécs, Department of Nuclear Medicine

Peptide Receptor Radionuclide Therapy (PRRT) of NET

Subject: PET Scan With or Without CT Attenuation. Original Effective Date: 11/7/2017. Policy Number: MCR: 610. Revision Date(s): Review Date:

Itroduction to the Nuclear Medicine: biophysics and basic principles. Zámbó Katalin Department of Nuclear Medicine

Case Report Metastatic Insulinoma Managed with Radiolabeled Somatostatin Analog

8/10/2016. PET/CT for Tumor Response. Staging and restaging Early treatment response evaluation Guiding biopsy

Radionuclides in Medical Imaging. Danielle Wilson

PET/CT imaging and RIT of prostate cancer. Kirsten Bouchelouche, MD, DMSc PET & Cyclotron Unit Rigshospitalet, Copenhagen Denmark

Bone PET/MRI : Diagnostic yield in bone metastases and malignant primitive bone tumors

Ronald C. Walker, MD, Prof of Radiology Vanderbilt University Medical Center Nashville, TN. Ga-DOTATATE PET/CT imaging Initial Vanderbilt experience

Neuroendocrine tumors: approaches to imaging

Dosimetry in Nuclear Medicine Therapies

PSMA PET in patients with prostate cancer

Nuclear Medicine: Basics to therapy

Whole Body MRI. Dr. Nina Tunariu. Prostate Cancer recurrence, progression and restaging

Neuroendocrine tumors (NETs) are characterized by the presence

MEDICAL POLICY SUBJECT: PEPTIDE RECEPTOR RADIONUCLIDE THERAPY (PRRT)

Managing Prostate Cancer After Initital Treatment Fails: Are There Good Next Steps?

New Concepts in PET Imaging Prostate Cancer

MEDICAL POLICY EFFECTIVE DATE: 06/21/07 REVISED DATE: 05/14/08, 04/16/09, 03/18/10, 03/17/11, 03/15/12, 02/21/13, 02/20/14, 02/19/15

Phillip J. Koo, MD Division Chief of Diagnostic Imaging Banner MD Anderson Cancer Center, USA

Tumor-Induced Osteomalacia

10/30/2018. Martha K. Terris, MD Witherington Distinguished Professor and Chair Medical College of Georgia Urology November 5, 2018

Whole body F-18 sodium fluoride PET/CT in the detection of bone metastases in patients with known malignancies: A pictorial review

PET Guidance of Therapy for BNCT and in vivo B-10 imaging

Prostate Cancer Local or distant recurrence?

Ryan Niederkohr, M.D. Slides are not to be reproduced without permission of author

Clinical indications for positron emission tomography

FDG-PET/CT in Gynaecologic Cancers

To report suspected adverse reactions to Axumin, call AXUMIN1 ( ) or contact FDA at FDA-1088 or

FDOPA, C11Choline, C11 Methionine. Dr K.G.Kallur

Dr Sneha Shah Tata Memorial Hospital, Mumbai.

PET/CT and PET/MR of Cardiac Tumors

FDG-18 PET/CT - radiation dose and dose-reduction strategy

Early detection of prostate cancer (PCa) may feasibly lead

Nuclear medicine in oncology. 1. Diagnosis 2. Therapy

PET in Prostate Cancer

Transcription:

Ga68 Imaging Roland HUSTINX Division of Nuclear Medicine and Oncologic Imaging Centre Hospitalier Universitaire de Liège Belgium

68 Ga Produced by a 68 Ge/ 68 Ga generator Decays by positron emission in 89% yield Emax of the positron 1.9 MeV 18 F: 0.63 MeV T1/2 68 minutes

68 Ge/ 68 Ga Generators 68 68 Ge T1/2 271 days Decays into a 100% electron capture mode at 106 kev in 68 Ga. [ nat Ga(p,xn) 68 Ge] or [ 69 Ga(p,n) 68 Ge] reactions in the nominal energy range 25 30 MeV (ideally 28 MeV) A 24-30 MeV cyclotron at 250μA can produce about 500 mci 68 Ge after 4-5 days irradiation eight 50 mci-generators per batch (500+ generators a year). Issues: Availability of 68 Ge / cost Sterility 68 Ge breakthrough 68 Ga can also be produced with an 18 MeV cyclotron

68Ge/68Ga Generators: «chemicals Vs pharmaceuticals» 4 manufacturers Berlin, Germany Cape Town, South Africa Munich, Germany Fleurus, Belgium

Radiopharmacy

Somatostatin Receptors Imaging Johnbeck et al. Future Oncol. (2014) 10(14), 2259 2277

Comparison with Octreoscan Higher sensitivity More convenient for the patient Faster results Lower radiation burden Less expensive Buchmann et al. Eur J Nucl Med Mol Imaging (2007) 34:1617 1626 Krausz et al. Mol Imaging Biol (2011) 13:583-593

Carcinoid 111 In-Octreoscan 68 Ga-DOTANOC

Biodistribution & Dosimetry Sandstrom et al. J Nucl Med 2013; 54:1755 1759 Velikyan et al J Nucl Med. 2014;55:204-210.

Clinical performances: TATE vs TOC

Wild et al. J Nucl Med. 2013;54:364-372.

Pancreatic NET, grade 1, Ki67 <1% 68 Ga-DOTANOC FDG

Gastrinoma, surgery, increased chromogranin: relapse? FDG 68 Ga-DOTANOC

Medullary Thyroid Carcinoma 68 Ga-DOTANOC

Relapse of MTC: TP for LN & bone met, FN for liver mets

Pitfall: insulinoma

DOTATATE & DOTANOC, 1 year apart NET, treated by SS analogue 68 Ga-DOTATATE 68 Ga-DOTANOC

68 Ga-DOTANOC 68 Ga-DOTATATE

Midgut NET, liver & LN mets, treated by SS analogue DOTATATE & DOTANOC 8 months apart 68 Ga-DOTANOC 68 Ga-DOTATATE

Pitfall: radiation therapy 4 years before

«68 Ga-DOTATOC PET/CT was considerably cheaper than 111 In-DTPA-octreotide with respect to both material and personnel costs. Furthermore, by using 68 Ga-DOTATOC PET/CT considerably fewer additional examinations were needed reducing the consequential costs significantly.»

68GA-DOTA-XXX: Quantitative imaging and dosimetry for individualized treatment Velikyan et al. J Nucl Med 2014; 55:204 210

79%

Graf et al. Int J Radiation Oncol Biol Phys, Vol. 85, No. 1, pp. 68-73, 2013

Glu-CO-Lys(Ahx)-[68Ga(HBED-CC)] 68 Ga-PSMA-HBED-CC 68 Ga-PSMA-11 «68 Ga-PSMA» PSMA: type II transmembrane glycoprotein Low expression by prostate cells Hyperxpression by prostate adenocarcinoma Exact function not known

Sensitivity Vs PSA level Perera et al. EUROPEAN UROLOGY 70 (2016) 926 937

Biochemical relapse: comparison with Choline Lesions Patients Schwenk et al Eur J Nucl Med Mol Imaging (2017) 44:92 101

Diagnostic accuracy Perera et al. EUROPEAN UROLOGY 70 (2016) 926 937

PSA 0.88 ng/ml Doubling time 12 Mo (bladder ca)

PSA 0.7 ng/ml

PSA 1.61 ng/ml: local recurrence + bone met

Specificity? «However, since 68Ga-PSMA-11-PET/CT was introduced, the results prove the excellent specificity of this compound indicating that any uptake of 68Ga-PSMA-11 above local background in CT- or MR morphological visible lesions of PCa-patients should be regarded as highly suspicious for PCa» (Afshar-Oromieh et al, J Nucl Med. 2017 Jan 6.) False positive results: Other cancers: lymphomas, follicular thyroid ca, sarcoma, rectal ca, HCC, NET, RCC, etc. Benign tumors: thyroid adenoma, schwannoma, meningioma, etc. Benign lesions: fractures, Paget s, stroke, sarcoidosis, anthracosis, etc. Normal variants: cervicothoracic (stellate) & coeliac LN

Lung adenocarcinoma Pancreatic adenocarcinoma: PSMA & FDG

Theranostics

PET/CT V/Q scanning? Galligas: 50 MBq 68 Ga in a Technegas generator - 10 MBq are inhaled 68 Ga-MAA : 50 MBq I.V. Activity ratios V/Q: 1/4 ldct followed by 2 PET acquisitions of 6-9 min. each

99m Tc ventilation SPECT 99m Tc-MAA perfusion SPECT 68 Ga ventilation PET 68 Ga-MAA perfusion PET Hofman et al. J Nucl Med. 2011;52:1513-1519.

68 Ga-EDTA PET/CT Imaging and Plasma Clearance for Glomerular Filtration Rate Quantification Hofman M et al. J Nucl Med 2015; 56:405 409

68 Ga, ready to take off?

Conclusions 68 Ga: Highly attractive combination Physical and chemical properties Cost/availability Already a clinical difference maker (SSRI & prostate cancer) Regulatory issues to be solved Small batches (few patients)